Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other financing activities (2020 - 2023)

Historic Other financing activities for 4D Molecular Therapeutics (FDMT) over the last 4 years, with Q2 2023 value amounting to $260000.0.

  • 4D Molecular Therapeutics' Other financing activities rose 12807.02% to $260000.0 in Q2 2023 from the same period last year, while for Jun 2024 it was $329000.0, marking a year-over-year decrease of 2471.4%. This contributed to the annual value of $468000.0 for FY2022, which is N/A changed from last year.
  • 4D Molecular Therapeutics' Other financing activities amounted to $260000.0 in Q2 2023, which was up 12807.02% from $69000.0 recorded in Q1 2023.
  • In the past 5 years, 4D Molecular Therapeutics' Other financing activities registered a high of $946000.0 during Q1 2021, and its lowest value of -$946000.0 during Q4 2021.
  • For the 4-year period, 4D Molecular Therapeutics' Other financing activities averaged around $74272.7, with its median value being $114000.0 (2022).
  • Over the last 5 years, 4D Molecular Therapeutics' Other financing activities had its largest YoY gain of 14947.15% in 2022, and its largest YoY loss of 7399.58% in 2022.
  • Over the past 4 years, 4D Molecular Therapeutics' Other financing activities (Quarter) stood at -$348000.0 in 2020, then tumbled by 171.84% to -$946000.0 in 2021, then skyrocketed by 149.47% to $468000.0 in 2022, then plummeted by 44.44% to $260000.0 in 2023.
  • Its last three reported values are $260000.0 in Q2 2023, $69000.0 for Q1 2023, and $468000.0 during Q4 2022.